检索结果-南通市图书馆

Tislelizumab in previously treated,locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2024年第3期36卷 257-269页

作者： Jian Li Ye Xu Aimin Zang Yunong Gao Quanli Gao Yanqiao Zhang Dong Wang jianming Xu ying Yuan Haiping Jiang Jieer ying Chunmei Shi Yanhong Deng jing Wang Tianshu Liu yi Huang Xiaoping Qian Yueyin pan ying Cheng Sheng Hu jin Wang Mengyue Shi Ke Wang Han Hu lin Shen State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers Beijing Key Laboratory of Carcinogenesis and Translational ResearchDepartment of Gastrointestinal OncologyPeking University Cancer Hospital&InstituteBeijing 100142China Department of Oncology Fudan University Shanghai Cancer CenterShanghai 200032China Department of Medical Oncology Affiliated Hospital of Hebei UniversityBaoding 071000China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of GynecologyPeking University Cancer Hospital&InstituteBeijing 100142China Department of Immunotherapy Henan Cancer HospitalZhengzhou 450001China Department of Gastrointestinal Oncology Affiliated Cancer Hospital of Harbin Medical UniversityHarbin 150086China Department of Gastrointestinal Oncology Chongqing University Cancer HospitalChongqing 400030China Department of Gastrointestinal Oncology the Fifth Medical CenterChinese PLA General HospitalBeijing 100048China Department of Medical Oncology the Second Affiliated HospitalZhejiang University School of MedicineHangzhou 310009China Department of Medical Oncology the First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Medical Oncology Cancer Hospital of the University of Chinese Academy of SciencesHangzhou 310022China Department of Medical Oncology Fujian Medical University Union HospitalFuzhou 350001China Department of Oncology the Sixth Affiliated HospitalSun Yat-sen UniversityGuangzhou 510655China Department of Medical Oncology Hunan Cancer HospitalChangsha 410013China Department of Medical Oncology Zhongshan HospitalFudan UniversityShanghai 200032China Department of Immunotherapy Hubei Cancer HospitalWuhan 430079China Department of Medical Oncology the Affiliated Hospital of Nanjing University Medical SchoolNanjing 210008China Department of Medical Oncology Anhui Provincial HospitalHefei 230001China Department of Medical Oncology Jilin Cancer Hospital

Objective:The open-label,phase II RATIONALE-209 study evaluated tislelizumab(anti-programmed cell death protein 1 antibody)as a tissue-agnostic monotherapy for microsatellite instability-high(MSI-H)/mismatch repair-deficient(dMMR)***:Adults with previously treated,locally advanced unresectable or metastatic MSI-H/dMMR solid tumors were *** received tislelizumab 200 mg intravenously every 3 *** response rate(ORR;primary endpoint),duration of response(DoR),and progression-free survival(PFS)were assessed by independent review committee(Response Evaluation Criteria in Solid Tumors v1.1).Results:Eighty patients were enrolled and treated;75(93.8%)patients had measurable disease at *** had metastatic disease and received at least one prior therapy for advanced/metastatic disease(n=79;98.8%).At primary analysis(data cutoff July 8,2021;median follow-up 15.2 months),overall ORR[46.7%;95%confidence interval(95%CI),35.1−58.6;one-sided P<0.0001]and ORR across tumor-specific subgroups[colorectal(n=46):39.1%(95%CI,25.1–54.6);gastric/gastroesophageal junction(n=9):55.6%(95%CI,21.2−86.3);others(n=20):60.0%(95%CI,36.1−80.9)]were significantly greater with tislelizumab vs.a prespecified historical control ORR of 10%;five(6.7%)patients had complete *** DoR,PFS,and overall survival were not reached with long-term follow-up(data cutoff December 5,2022;median follow-up 28.9 months).Tislelizumab was well tolerated with no unexpected safety ***-related adverse events(TRAEs)of grade≥3 occurred in 53.8%of patients;7.5%of patients discontinued treatment due to ***:Tislelizumab demonstrated a significant ORR improvement in patients with previously treated,locally advanced unresectable or metastatic MSI-H/dMMR tumors and was generally well tolerated.

关键词： Biomarkers DNA mismatch repair immune checkpoint inhibitors microsatellite instability phase II clinical trials programmed cell death 1 receptor

浙江遂昌地区同域分布猪獾与花面狸时空生态位比较

在线全文

学校读者我要写书评

暂无评论

兽类学报 2024年第3期44卷 297-308页

作者：赵家乐龚笑飞潘江炎李悦温作豪叶毅高建明赵阿勇林植华浙江农林大学动物科技学院·动物医学院临安311300 遂昌县生态林业发展中心遂昌323300 南京师范大学生命科学学院南京210023 丽水学院生态学院丽水323000

猪獾(Arctonyx collaris)与花面狸(Paguma larvata)是浙江遂昌山地小型食肉兽中的优势物种,具有相似的食性和环境选择。为探明同域分布的猪獾与花面狸的共存机制,于2020年6月至2022年6月,在浙江省遂昌县5个样区(白马山、千佛山、九龙山... 详细信息

猪獾(Arctonyx collaris)与花面狸(Paguma larvata)是浙江遂昌山地小型食肉兽中的优势物种,具有相似的食性和环境选择。为探明同域分布的猪獾与花面狸的共存机制,于2020年6月至2022年6月,在浙江省遂昌县5个样区(白马山、千佛山、九龙山、牛头山和湖山)进行红外相机监测,选取相机布设位点71个,布设123台红外相机,总有效工作日19654个,独立有效事件2184次,使用物种分布模型和日活动节律模型对该地区的猪獾与花面狸的时空生态位进行分析。结果表明:(1)两者为当地中级捕食者中的优势物种,但猪獾(RAI=9.26)的相对多度指数高于花面狸(RAI=3.96);(2)两者对于生境选择具有较高相似性,空间生态位上的重叠系数为:D=0.783,I=0.960;(3)两者昼夜活动差异极显著(P<0.01),猪獾昼夜均有活动,花面狸主要在夜间活动。猪獾与花面狸在空间生态位上存在较大程度重叠,但在时间生态位上存在较大程度分化,表明两者之间倾向于通过反应性策略共存。本研究结果初步揭示了猪獾与花面狸的时空生态位特征与共存机制,为深入理解同域中级捕食者种间关系及区域内生物多样性的保护提供实例和理论参考。

关键词：猪獾花面狸生态位种间关系日活动节律

Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology

在线全文

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2019年第1期16卷 189-204页

作者： Xuchao Zhang Zhiyong Liang Shengyue Wang Shun Lu Yong Song ying Cheng jianming ying Weiping Liu yingyong Hou Yangqiu Li yi Liu Jun Hou Xiufeng Liu Jianyong Shao Yanhong Tai Zheng Wang Li Fu Hui Li Xiaojun Zhou Hua Bai Mengzhao Wang You Lu jinji Yang Wenzhao Zhong Qing Zhou Xuening Yang Jie Wang Cheng Huang Xiaoqing Liu Xiaoyan Zhou Shirong Zhang Hongxia Tian Yu Chen Ruibao Ren Ning Liao Chunyan Wu Zhongzheng Zhu Hongming pan Yanhong Gu Liwei Wang Yunpeng Liu Suzhan Zhang Tianshu Liu Gong Chen Zhimin Shao Binghe Xu Qingyuan Zhang Ruihua Xu lin Shen yilong Wu Guangdong Lung Cancer Institute Medical Research Center Cancer Center of Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences Affiliated Guangdong Provincial People's Hospital South China University of Technology Department of Pathology Peking Union Medical College Hospital Chinese Academy of Medical Sciences National Research Center for Translational Medicine Shanghai Rui Jin Hospital Shanghai Jiao Tong University School of Medicine Lung Tumor Clinical Medical Center Shanghai Chest Hospital Shanghai Jiao Tong University Division of Respiratory Medicine Jinling Hospital Nanjing University School of Medicine Department of Oncology Jilin Cancer Hospital Department of Pathology National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Department of Pathology West China Hospital Sichuan University Department of Pathology Zhongshan Hospital Fudan University Department of Hematology First Affiliated Hospital Institute of Hematology School of Medicine Jinan University Laboratory of Oncology Affiliated Hospital of the Academy of Military Medical Sciences Department of Oncology First Clinical College of South China University of Technology/Guangdong Lung Cancer Institute People's Liberation Army Cancer Center of Bayi Hospital Affiliated to Nanjing University of Chinese Medicine Department of Pathology Sun Yat-sen University Cancer Center Department of Pathology Affiliated Hospital of the Academy of Military Medical Sciences Department of Pathology Beijing Hospital Department of Breast Cancer Pathology and Research Laboratory of Cancer Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin Tianjin’s Clinical Research Center for Cancer Department of Pathology Jinling Hospital Nanjing University School of Medicine State Key Laboratory of Molecular Oncology Department of Medical Oncology National Cancer Center/Canc

Next-generation sequencing(NGS) technology is capable of sequencing millions or billions of DNA molecules ***, it represents a promising tool for the analysis of molecular targets for the initial diagnosis of disease, monitoring of disease progression, and identifying the mechanism of drug resistance. On behalf of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology(CSCO) and the China Actionable Genome Consortium(CAGC), the present expert group hereby proposes advisory guidelines on clinical applications of NGS technology for the analysis of cancer driver genes for precision cancer therapy. This group comprises an assembly of laboratory cancer geneticists, clinical oncologists, bioinformaticians,pathologists, and other professionals. After multiple rounds of discussions and revisions, the expert group has reached a preliminary consensus on the need of NGS in clinical diagnosis, its regulation, and compliance standards in clinical sample collection. Moreover, it has prepared NGS criteria, the sequencing standard operation procedure(SOP), data analysis, report, and NGS platform certification and validation.

关键词： Next-generation sequencing technology cancer consensus

2022年CHINET三级医院细菌耐药监测

在线全文

学校读者我要写书评

暂无评论

中国感染与化疗杂志 2024年第3期24卷 277-286页

作者：郭燕胡付品朱德妹汪复蒋晓飞徐英春张小江张峰波季萍谢轶肖玉玲王传清付盼徐元宏黄颖孙自镛陈中举孙景勇陈庆褚云卓田素飞胡志东李金俞云松林洁单斌许云敏郭素芳王艳艳魏莲花李可可张泓潘芬胡云建艾效曼卓超苏丹虹郭大文赵金英喻华黄湘宁刘文恩李艳明金炎邵春红徐雪松李威王山梅楚亚菲张利侠马娟周树平周艳朱镭孟晋华董方吕志勇胡芳芳沈瀚周万青贾伟李刚吴劲松卢月梅李继红孙倩段金菊康建邦马晓波郑燕青郭如意朱焱陈运生孟青王世富胡雪飞黄文辉李娟石泉贵杨娟热孜瓦古丽·阿不力米提黄莉莉邵雪君任晓艳李冬张群陈雪黎日海徐洁丽高凯杰徐璐林琳张卓刘健龙付敏郭映辉张文超王增国贾凯夏云孙珊杨慧敏苗艳周明明张诗海刘红娟陈楠李婵沈继录门万琪王鹏张晓威刘彦彦安勇复旦大学附属华山医院抗生素研究所国家卫健委抗生素临床药理重点实验室上海200040 北京协和医院新疆医科大学第一附属医院四川大学华西医院复旦大学附属儿科医院安徽医科大学第一附属医院华中科技大学同济医学院附属同济医院上海交通大学医学院附属瑞金医院中国医科大学附属第一医院天津医科大学总医院浙江大学医学院附属邵逸夫医院昆明医科大学第一附属医院内蒙古医科大学附属医院甘肃省人民医院上海交通大学医学院附属儿童医院北京医院广州医科大学附属第一医院哈尔滨医科大学附属第一医院四川省人民医院中南大学湘雅医院山东省立医院吉林大学中日联谊医院河南省人民医院陕西省人民医院江西省儿童医院山西省儿童医院首都医科大学附属北京儿童医院贵州省人民医院南京大学医学院附属鼓楼医院宁夏医科大学总医院深圳市人民医院河北医科大学第二医院山西医科大学第二医院厦门大学附属第一医院福建省泉州市第一医院深圳市儿童医院山东大学齐鲁儿童医院南昌大学第一附属医院青海大学附属医院西藏军区总医院乌鲁木齐市第一人民医院(乌鲁木齐儿童医院) 苏州大学附属儿童医院云南省腾冲市人民医院重庆医科大学附属儿童医院广西桂平市人民医院河南省儿童医院沈阳市儿童医院湖南省儿童医院河北省儿童医院西安市儿童医院重庆医科大学附属第一医院陕西省神木市医院浙江省儿童医院安徽省儿童医院天津市儿童医院安徽医科大学第四附属医院长春市儿童医院邢台市第九医院复旦大学附属华山医院检验科国家卫健委抗生素临床药理重点实验室上海200040

目的监测2022年CHINET三级医院临床分离菌对抗菌药物的敏感性。方法国内58所三级医院临床分离菌采用纸片扩散法或商品化药敏试验自动测试仪按CHINET统一监测技术方案进行抗菌药物敏感性试验。结果按CLSI M1002022年版折点标准判断。结... 详细信息

目的监测2022年CHINET三级医院临床分离菌对抗菌药物的敏感性。方法国内58所三级医院临床分离菌采用纸片扩散法或商品化药敏试验自动测试仪按CHINET统一监测技术方案进行抗菌药物敏感性试验。结果按CLSI M1002022年版折点标准判断。结果收集2022年1月1日-12月31日上述医院临床分离菌共318013株,其中革兰阳性菌占29.5%,革兰阴性菌占70.5%。金黄色葡萄球菌、表皮葡萄球菌和其他凝固酶阴性葡萄球菌(除假中间葡萄球菌和施氏葡萄球菌外)中甲氧西林耐药株的检出率分别为28.3%、76.7%和77.9%。MRSA中有94.0%的菌株对甲氧苄啶-磺胺甲噁唑敏感;MRSE中有90.8%的菌株对利福平敏感,未发现万古霉素耐药株。肠球菌属中粪肠球菌对多数测试抗菌药物的耐药率均显著低于屎肠球菌,两者中均有少数万古霉素耐药株。2022年儿童和成人中分离的非脑膜炎肺炎链球菌中PSSP的检出率分别为94.2%和95.7%。除克雷伯菌属细菌对碳青霉烯类的耐药率范围为21.7%~23.1%外,其他细菌的耐药率多在13.1%以下。除天然耐药菌株外,其他肠杆菌目细菌对替加环素、黏菌素和多黏菌素B高度敏感,耐药率范围为0.1%~13.3%。铜绿假单胞菌对美罗培南的耐药率从2019年的23.5%下降至2022年的18.0%;鲍曼不动杆菌对美罗培南的耐药率亦从2019年的79.0%下降至2022年的72.5%。结论三级医院临床分离菌对常见抗菌药物的耐药率仍呈增长趋势,但碳青霉烯类耐药肺炎克雷伯菌、铜绿假单胞菌、鲍曼不动杆菌等多种重要耐药细菌的检出率近年来呈现连续下降趋势,提示加强细菌耐药监测,开展多学科联动的方式对控制耐药细菌的流行播散是行之有效的。

关键词：三级医院细菌耐药监测药物敏感性试验碳青霉烯类耐药革兰阴性杆菌